Summary
CVS Caremark Corporation (formerly CVS Corporation) filed its quarterly report for the period ending September 29, 2007. The report details the significant financial and operational impact of the Caremark merger, which closed on March 22, 2007. The merger has substantially increased the company's scale, particularly in the Pharmacy Services segment, and has led to a considerable rise in reported revenues and operating expenses due to the integration of Caremark's operations and the associated accounting for goodwill and intangible assets. The company is actively managing its capital structure, evidenced by substantial share repurchases and the issuance of new senior notes and preferred securities. The company's financial performance reflects the combination of its retail pharmacy business and the newly integrated pharmacy benefit management services. While revenues have grown significantly, driven by the merger, investors should note the increased operating expenses, particularly amortization of intangible assets, and the ongoing integration costs. Management highlights the continued benefits from generic drug utilization and purchasing synergies, alongside challenges such as increasing scrutiny from third-party payors and pricing pressures. The company anticipates that cash flows from operations, supported by financing, will be sufficient to fund future growth and integration efforts.
Key Highlights
- 1The Caremark merger, completed on March 22, 2007, significantly impacted financial results, leading to a substantial increase in net revenues and operating expenses. Goodwill and intangible assets have increased significantly post-merger.
- 2The Pharmacy Services segment saw a dramatic increase in net revenues (from $933.5 million to $10,662.6 million for the quarter) due to the inclusion of Caremark's operations.
- 3Consolidated net earnings for the nine months ended September 29, 2007, rose by 91.4% to $1.82 billion compared to the prior year period, reflecting the combined entities' performance.
- 4The company repurchased approximately 10.3 million shares through a tender offer and initiated a $5.0 billion share repurchase program, including a $2.5 billion accelerated share repurchase (ASR) agreement, resulting in the acquisition of 61.7 million shares by September 29, 2007.
- 5CVS Caremark issued new debt, including $1.75 billion in Floating Rate Senior Notes and $1.0 billion in 6.25% unsecured senior notes, along with $1.0 billion in Enhanced Capital Advantaged Preferred Securities (ECAPS), to repay existing debt.
- 6The company has implemented new accounting standards, including FIN 48 for uncertainty in income taxes, and continues to evaluate the preliminary allocation of the purchase price for the Caremark merger.
- 7The report details ongoing litigation, including a settled shareholder derivative lawsuit related to stock option practices and ongoing investigations into PBM business practices, though none are expected to be material individually.